This appeared last week:
Beamtree (ASX:BMT) partners with CALHN for safer patient care
ASX:BMT MCAP $136.9M
Jessica De Freitas Markets Reporter
30 September 2021 15:30 (AEST)
- Beamtree (BMT) partners with the Central Adelaide Local Health Network (CALHN) to implement AI products to support safer care for patients
- The companies will implement a data quality product across CALHN's hospital network as well as launch a new trial using RippleDown
- The trial supports clinical decision making for pathology services and will integrate the Ainsoff Index into the electronic medical record
- The collaboration also involves assessing RippleDown in clinical workflow to get feedback from practicing doctors
- Company shares end the day 20.2 per cent in the green to close at 59.5 cents
Beamtree (BMT) has partnered with the Central Adelaide Local Health Network (CALHN).
The partnership will see the pair implement artificial intelligence (AI) products to support better and safer care for patients.
Specifically, the companies will implement the RISQ data quality product across CALHN's network of four hospitals. RISQ is a comprehensive measurement and auditing tool which supports better health data accuracy and the management of potential hospital-acquired complications.
Beamtree and CALHN will also launch a new trial using RippleDown, an AI decision support product, and launch the Ainsoff index which is used to detect deterioration in its early stage.
BMT CEO, Tim Kelsey, commented on the partnership.
"This strategic partnership is an outcome of our commitment to improving patient outcomes through the early identification of risk, benchmarking and AI-led decision support. Together, we have the opportunity to enhance healthcare service quality, safety, accuracy and insight that will improve health systems in Adelaide and beyond."
Over the next six months, the companies will conduct a trial using RippleDown to support clinical decision making for pathology services and will integrate the Ainsoff Index into the electronic medical record. This is the first public hospital implementation of the Ainsoff Index since Beamtree acquired Ainsoff last month.
Beamtree Clinical Lead surgeon, Dr Levi Bassin, commented on the implementation of the Ainsoff Index.
"The implementation of the Ainsoff Index for deterioration in one of Australia’s largest public hospitals is a great step forward and clearly demonstrates the value of joining with Beamtree to gain broader support for implementations, ultimately helping more patients and clinicians across Australia."
The collaboration also comes with the opportunity to co-develop a new implementation of RippleDown in clinical workflow. The aim of this will be to get feedback from practicing doctors to ensure the tool supports diagnostic ordering for safety and quality.
The revenue of the implementation will be over $300,000 to establish the proof of concept in the public health setting.
Here is the link:
This page has a lot of announcements and background:
https://au.linkedin.com/company/clinical-decision-support
Those who came in late may not be aware his company has Mr Tim Kelsey (late of ADHA) as its CEO.
The company seems to be in the business aggregating and then processing clinical data under a proprietary framework called ‘RippleDown”
The “Ainsoff Index” is a very newly invented index to use EHR data to detect clinical deterioration.
This all seems to be pretty experimental stuff so it will be worth just keeping an eye on it to see what outcomes develop in yet another patient data manipulation and evaluation exercise.
David.
10 comments:
After decades working in this field I have concluded that I must have been living on another planet; probably Jupiter or Mars!
I am bewildered by the jargonised rhetoric. Who is selling who 'what'? I have no idea; does anyone in BMT have any idea? The media release sounds frightfully sophisticated to the point I cannot make head or tail of what they are saying or claiming.
Could someone please explain what it is all about using simple, unambiguous, clear English. Thanks.
The fact Tim Kelsey is involved suggests a whole lot of data mining without consent. I am sure it will reap lots of tax payer dollar and results in unmeasurable outcomes. Surely his visa has expired?
Do a search for "Ainsoff index" and all you will find are this blog and Beamtree.
"The implementation of the Ainsoff Index for deterioration.." sounds exactly what it is - sales spin.
There are no scientific papers or any other reputable reference that mention it.
Anyone who implements any sort of healthcare decision support/making system needs their head looking at.
If the software does what it is claimed to do it should be regulated by the Therapeutic Goods Administration. There is no claim or evidence that it is regulated, therefore it is probably safe to assume that:
a) its doesn't do much of value, and so isn't regulated or
b) it should be, but isn't, regulated.
And the same for Rippledown.
https://www.tga.gov.au/regulation-software-based-medical-devices
Flowcharts showing which software products are regulated as a medical device, and those that are not.
https://www.tga.gov.au/sites/default/files/my-software-regulated.pdf
and I doubt that Timmie knows the difference between AI and Visual BASIC.
Timmie's visa may not have expired but his welcome has.
This is a case of reaping what you sow. For a decade now anyone with depth of knowledge or a natural talent for spotting BS have been nudged out of health IT. This allows life forms such as Kelsey and his masters to take “brochureware” fools for a ride.
Odd how this unproven technology can be implemented yet other vendors are excluded because they have no reference Le implementation sites?
My comment at 6:34PM is worthy of the reward offered by David. I wish to share it equally with those commentators who subsequently responded with such clarity illuminating BMTs smoke and mirrors BS.
Ansoff or Ainsoff Matrix!!?? Are they the same?
Ansoff Matrix - Wikipediahttps://en.wikipedia.org › wiki › Ansoff_Matrix
The Ansoff Matrix is a strategic planning tool that provides a framework to help executives, senior managers, and marketers devise strategies for future ...
Ahhh Tim Kelsey excelling at what he does best!
Best to invest (not).
Ainsoff has nothing to do with Igor Ansoff, a Russian American who died in 2002 or his matrix.
Ainsoff is a company that has developed a bunch of algorithms based upon a rather small set of data.
https://www.ainsoff.com/ says
"OUR INNOVATIVE TECHNOLOGY
We perform real time quantitative analysis of patient data on your IT system. Our risk prediction model has been developed on over 300,000 patient encounters, allowing us to mimic experienced clinicians and detect patient deterioration well in advance of extremis.
Our finely tuned natural language processing software accurately documents diagnoses specialists often miss."
it also says "Published trial results coming soon."
It rather reminds me of the dot com boom when gullible people bought into companies that made outlandish claims and promises just because they used the internet.
This sort of AI and Machine Learning is little more than glorified curve fitting. You scan electronic medical records of patients looking for sudden changes in patient data and create an alert if you find one.
The claim is that "Ainsoff helps reduces the risk of death for seriously ill patients and automates key clinical processes."
https://www.crunchbase.com/organization/ainsoff
I can't see how this reduces the risk of a death. It might identify that a risk has gone up, but it cannot, on its own, reduce the risk.
My guess is that Beamtree has paid $1million for a reference site in Australia in what it can call AI.
It supports this initiative
https://beamtree.com.au/beamtree-partners-with-usyd-data/
"The Beamtree and University of Sydney collaboration will see the first senior academic appointment in clinical informatics in Australia – the Beamtree Associate Professor of Clinical Informatics. The appointment will lead a new research team in the Faculty of Medicine and Health at The University of Sydney to innovate in the use of health data so that cutting-edge approaches to biomedical informatics and AI can support sustainable, high-quality health care around the world.
The appointment will lead the research efforts across several areas, including:
* New methods for making patient data available to support clinical decision support tools
* Better mapping patient data to assist in research and clinical surveillance activities
* Applying machine learning and other data science models to patient data"
Associate Professor of Clinical Informatics is hardly a "senior academic appointment" I can find no evidence that the position exists yet or that they have started to advertise the role.
A search of Sydney University's website gets no hits on "Clinical Informatics" so it looks as though that five year collaboration hasn't started yet.
AI and Machine learning is a highly competitive and expensive academic field that has yet to show much in the way of return on effort over and above deterministic algorithms, especially with soft data like medical tests and observations.
Beamtree needs to have deep pockets if it wants to play with the big boys, and an Associate Professor is no big boy (or girl).
As the old joke goes:
How do you create a small AI company? Start with a big one.
Thank you for that particularly excellent commentary Bernard.
It seems that when they say
"Beamtree (BMT) partners with the Central Adelaide Local Health Network (CALHN) to implement AI products to support safer care for patients"
what they really mean is they will be conducting a trial of a proof of concept.
This ASX document https://hotcopper.com.au/data/announcements/ASX/2A1327067_BMT.pdf
says
"As a part of the strategic partnership, Beamtree will be co-developing a new implementation of RippleDown® in the clinical workflow. This Proof of Concept will create a knowledge base to support ordering of diagnostics in the context of the patient’s individual care and circumstances. The goal will be to capture feedback from practicing doctors to ensure that the tool supports appropriate diagnostic ordering for safety and quality in line with best evidence."
and
"The revenue on this implementation will be over $300,000 to establish the Proof of Concept in the public health setting."
Which probably explains the lack of any TGA requirements. It is not a patient care system it is a system that supports the ordering of diagnostic tests.
@2:45PM I think a bank of high-flying cumulo-nimbus clouds best describes the "strategic partnership .... and new implementation of RippleDown Proof-of-Concept".
Post a Comment